Alessandra Ciullo

Alessandra Ciullo

Auto-generated profile, based on publicly available information

Alessandra Ciullo

Cedars-Sinai Medical Center, Smidt Heart Institute, Los Angeles, CA 90048, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2024 in European Heart Journal
Verified
Journal Article
Open access
PDF file
ACAlessandra Ciullo
Alessandra Ciullo
LLLiang Li
Liang Li
CLChang Li
Chang Li
KTKara Tsi
Kara Tsi
CFColin Farrell
Colin Farrell
AIAhmed Ibrahim
Ahmed Ibrahim
Extracellular vesicles (EVs) secreted by cardiosphere-derived cells exert immunomodulatory effects through the transmission of small non-coding RNAs. The mechanism and role of yREX3, a small Y RNA abundant in EVs in myocardial injury, was investigated. yREX3 attenuates cardiac ischaemic injury by selective DNA methylation. Synthetic yREX3 encapsulated in lipid nanoparticles triggers broad transcriptomic changes in macrophages, localizes to the nucleus, and mediates epigenetic silencing of protein interacting with C kinase-1 (Pick1) through methylation of upstream CpG sites. Moreover, yREX3 interacts with polypyrimidine tract binding protein 3 (PTBP3) to methylate the Pick1 gene locus in a DNA methyltransferase–dependent manner. Suppression of Pick1 in macrophages potentiates Smad3 signalling and enhances efferocytosis, minimizing heart necrosis in rats with myocardial infarction. Adoptive transfer of Pick1-deficient macrophages recapitulates the cardioprotective effects of yREX3 in vivo. These findings highlight the role of a small Y RNA mined from EVs with a novel gene-methylating mechanism. Small non-coding RNA, yREX3, induces methylation-mediated silencing of Pick1. Pick1 silencing in macrophages enhances their capacity to clear dead cells and promote tissue healing after injury.

3 December 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
AIAhmed Ibrahim
Ahmed Ibrahim
ACAlessandra Ciullo
Alessandra Ciullo
HKHiroaki Komuro
Hiroaki Komuro
KMKazutaka Miyamoto
Kazutaka Miyamoto
XJXaviar M. Jones
Xaviar M. Jones
EMEduardo Marbán
Eduardo Marbán
Noncoding RNAs (ncRNAs) are increasingly recognized as promising therapeutic candidates. Here, we report the development of therapeutic Y RNA 1 (TY1), a synthetic ncRNA bioinspired by a naturally occurring human small Y RNA with immunomodulatory properties. TY1 up-regulates three-prime DNA exonuclease 1 (TREX1), an exonuclease that rapidly degrades cytosolic DNA. In preclinical models of myocardial infarction (MI) induced by ischemia-reperfusion, TY1 reduced scar size. The cardioprotective effect of TY1 was abrogated by prior depletion of macrophages and mimicked by adoptive transfer of macrophages exposed to either TY1 or Trex1 overexpression. Inhibition of Trex1 in macrophages blocked TY1 cardioprotection. Consistent with a central role for Trex1 , TY1 attenuated DNA damage in the post-MI heart. The key beneficial effects appear to be mediated by extracellular vesicles secreted by TY1-conditioned macrophages. This previously undescribed mechanism—pharmacological up-regulation of Trex1 in macrophages—establishes TY1 as the prototype for a new class of ncRNA drugs with disease-modifying bioactivity. We refer to this potential new class of ncRNA drugs as exomers because of the identification of their parent molecules in extracellular vesicles.

7 November 2023 in Circulation
Verified
Journal Article
Closed access
XJXaviar M Jones
Xaviar M Jones
ACAlessandra Ciullo
Alessandra Ciullo
TMThassio Mesquita
Thassio Mesquita
RRRussell Rogers
Russell Rogers
AIAhmed Ibrahim
Ahmed Ibrahim
EMEduardo Marban
Eduardo Marban

8 November 2022 in Circulation
Verified
Journal Article
Closed access
XJXaviar M Jones
Xaviar M Jones
ACAlessandra Ciullo
Alessandra Ciullo
TMThassio Mesquita
Thassio Mesquita
LLLiang Li
Liang Li
MFMario Fournier
Mario Fournier
EMEduardo Marban
Eduardo Marban